2021.10.26 09:10 Fun-Trust-8023 Friends…massive lying operation?
I need advice—that’s to say if I’m taking things too personally or just need a wake up call.
I’ve been friends with these ladies for the better part of 10 years. We met in college—and have even lived together off and on. Turns out that was strained during covid and the relationship was on the line. We settled or so I thought our differences and current live in the same complex.
This weekend I texted our friend group and asked about Saturday plans. Initially there was no response but then one of my friends said oh—we’ll be out of town starting Friday. To I responded “where?!” She responded that they’re flying to DC. I was a little surprised. Keep in mind these are my BFFs and you’d think they’d let me about a planned trip to this scale. Even more so—they’ve been acting distant and avoiding me because I don’t think they wanted to invite me, etc. The thing is I’ve been to DC for travel many times and wouldn’t wanted to go. They didn’t ask me to watch the cats or even drive them to the airport in order to avoid me finding out. Keep in mind I literally live across the street! They also haven’t sent any trip highlights or photos to our group chat. It’s just all so weird and I am hurt. It feels like they don’t want me around and now I’m even questing if they feel as strongly about the friendship as I do?
I wish making adult friends wasn’t so difficult but maybe this is a lesson I need to expand my friend group. Advice?
submitted by Fun-Trust-8023 to relationship_advice [link] [comments]
2021.10.26 09:10 QuietInNature Instock alert: 75309 Republic Gunship and 10272 Manchester United Stadium at Lego.com
I’ve been watching both, but can’t bring myself to pull the trigger this morning. Back in stock at MSRP!
submitted by QuietInNature to lego [link] [comments]
2021.10.26 09:10 MirrorimagineM7 The Limited time mission Reward is the Rick Gigan/Gigan (Space)/Gigan (Sleeves use)/ Gigan from Godzilla!
|submitted by MirrorimagineM7 to GBO2 [link] [comments]|
2021.10.26 09:10 DrSatan420247 Tenacious D lifted their whole shtick from Kids in the Hall
I was watching season 2 of Kids in the Hall and realized that JB and KG lifted the entire concept and most of the really good bits in The Pick of Destiny, including their whole rock off with the devil, from this KITH. Amazing to think they made an entire feature film and a music video off of a 6 minute bit from a (now) obscure sketch comedy show.
Kids in the Hall:
submitted by DrSatan420247 to FanTheories [link] [comments]
2021.10.26 09:10 stalingradsniper Please SHIBarmy help me
34(M) from Australia. I know nothing of crypto at all. But it looks like shib is about to go through the roof. And I have missed every financial opportunity that I should have taken in my life. I still live paycheck to paycheck and I am not missing out on this one. Please reach me everything I have to know. What app I need to use. How I get started etc. Regards Stalingradsniper
submitted by stalingradsniper to SHIBArmy [link] [comments]
2021.10.26 09:10 Crims0nCrow3 Can you fight the manticore with ground tames or does it never land. Also the abb boss only drakes?
2021.10.26 09:10 vagabond_demon Elegant in fiery red dress
|submitted by vagabond_demon to AnadeArmas [link] [comments]|
2021.10.26 09:10 SofaKingHornKnee The problem with Cursed Realm
First let me preface this by saying I know this community tends to be quite reactive when it comes to new, game chancing content. However, I think the new feature "Cursed Realm" has a major problem. While it certainly isn't gonna cause the downfall of this game I do think it will leave a bitter taste in many players mouths. The issue is that this is the first feature to be accessible by other means than campaign progression, as to ender Cursed Realm you need to meat certain RC crystal requirements. The issue I have with this is, that the majority of players apart from veterans and whales will most likely be unable to participate in this game mode. It would have been much better if Cursed Realm was unlocked once you reached chapter 37 and was divided into level brackets like In twisted realm. Doing it this would would allow players to eventually make it into Cursed Realm rather than being permanently blocked out from new (and from the looks of it quite exciting) content. Please let me know what you all thing about this new feature.
submitted by SofaKingHornKnee to afkarena [link] [comments]
2021.10.26 09:10 digikrynary 10 years. D&D Nerds. Let’s go!!
|submitted by digikrynary to cakeday [link] [comments]|
2021.10.26 09:10 StatsmanFPL Worst Defensive Teams
|submitted by StatsmanFPL to FantasyPL [link] [comments]|
2021.10.26 09:10 earthmoonsun PIC
|submitted by earthmoonsun to nocontextpics [link] [comments]|
2021.10.26 09:10 AlbusDumbeldoree Recommendations for a standing desk
2021.10.26 09:10 Broopyd [Chris Wheatley] Patino not involved tonight.
|submitted by Broopyd to Gunners [link] [comments]|
2021.10.26 09:10 Elotan5 Day1 drawing countryballs
|submitted by Elotan5 to countryballs_comics [link] [comments]|
2021.10.26 09:10 DJ__stonez MAN UNITED bought a GOAT 🐐 LIVERPOOL Roasted it for SALAH celebration 😂 (5-0 )💀😂
|submitted by DJ__stonez to younestalksfootball [link] [comments]|
2021.10.26 09:10 lol_objection names to give to your blue chicken
|submitted by lol_objection to Deltarune [link] [comments]|
2021.10.26 09:10 rockitseven Looking for an Adult community? No theft? No grief? We are all waiting for you on TogetherCraft! • JAVA • Whitelist • Hermitcraft Inspired • Player Shops • Weekly Community Events • PVE Focused • Diamond Economy • Extra Large Map • Ready to join our friendly community? www.togethercraft.online
|submitted by rockitseven to MinecraftServerFinder [link] [comments]|
2021.10.26 09:10 Swiss666 A catch on Halloween night [@TNfp79]
|submitted by Swiss666 to bakudeku [link] [comments]|
2021.10.26 09:10 blue-paper-clip I still wonder "what if...".
To my work crush,
I still wonder "what if..." years later. What if I had to courage to ask you out on a date? What if I bought you flowers? I wasn't so nervous around you? What If we became friends? What if you felt the same? What if you still think about me too? What if you would've said NO to me asking you out? What if you would've said YES? What if we started dating back then? What If we were still together? What if we ended up tying the knot? What if we ended up having a few kids of our own? What if we had a few dogs of our own and named them Scooby & Scrappy? What if today we were a few years in into our marriage and the love faded? What if our relationship and our love was exactly like in The Notebook? What if our relationship ended like Lorena Bobbitt? What if I died before you? What if you died before me?
Perhaps that's what I'm scared of. I'm scared of losing you. I'm scared of getting my heart broken. I'm scared of being rejected by you. I'm scared of you thinking I'm not worth it. I'm scared my feelings wouldn't be mutual.
What if you felt the same?
submitted by blue-paper-clip to UnsentLetters [link] [comments]
2021.10.26 09:10 janjicm No way man, did others clap as well?
|submitted by janjicm to thatHappened [link] [comments]|
2021.10.26 09:10 Onlyheretoreplylol Ayy my first concerned redditor message 🥳🥳🥳
2021.10.26 09:10 bingdingboomow I think this is an ASU57 on wheels :)
|submitted by bingdingboomow to TankPorn [link] [comments]|
2021.10.26 09:10 Huck_el_berry INOVIO Completes Enrollment of Phase 1B Clinical Trial for its DNA Vaccine Candidate Against Lassa Fever, INO-4500, in West Africa 8:00 AM ET 10/26/21 | Dow Jones Milestone for INO-4500 illustrates INOVIO's commitment to combatting infectious diseases
PLYMOUTH MEETING, Pa., Oct. 26, 2021 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced its Phase 1B clinical trial for INO-4500, its DNA vaccine candidate for Lassa fever, completed full enrollment of 220 participants. This trial (LSV-002 - NCT04093076) is ongoing at the Noguchi Memorial Institute for Medical Research in Accra, Ghana, and is the first vaccine clinical trial for Lassa fever conducted in West Africa, where the viral illness is endemic.
INOVIO is advancing INO-4500 with full funding from the Coalition for Epidemic Preparedness Innovations (CEPI), a global partnership between public, private, philanthropic, and civil society organizations to stimulate and accelerate the development of vaccines against emerging infectious diseases and enable access to these vaccines for people in need during outbreaks. The company was awarded up to US $56 million from CEPI in 2018 under which INOVIO is advancing vaccine candidates against Lassa fever and Middle East Respiratory Syndrome (MERS). INOVIO and CEPI plan to establish a stockpile of these vaccines for emergency use after Phase 2 testing, if successful. As part of CEPI's $3.5 billion plan to reduce, or even eradicate, the risk of epidemics and pandemics, CEPI's goal is to get a licensed Lassa vaccine for use in endemic countries. The forward-looking strategy also includes the aim to advance clinical trial capacity, infrastructure, and expertise in low- and middle-income countries.
Dr. Laurent Humeau, INOVIO's Chief Scientific Officer, said, "Completing enrollment of LSV-002 is an important milestone for the clinical development of INO-4500, our DNA vaccine candidate against Lassa fever. INOVIO and our partners are committed to addressing this significant unmet public health need, considering the prevalence of the Lassa virus, the potential severity of Lassa fever, and the lack of any licensed vaccines or other treatments for this disease. We are grateful to CEPI for their support as we work with our partners to advance INO-4500."
Dr. Humeau added, "This milestone represents another example of the progress we are making across INOVIO's infectious disease portfolio, including our late-stage development efforts with INO-4800 against COVID-19 as well as advancements with INO-4700 against MERS."
Dr. Melanie Saville, Director of Vaccine R&D at CEPI, said, "I am delighted to see the rapid progress in enrollment for this pivotal trial to assess the safety and immunogenicity of INOVIO's promising Lassa vaccine candidate in Ghana. At a time when much scientific attention is drawn towards COVID-19, it is critical that we continue to progress research against this potentially fatal disease which affects many countries across the West African region. Data provided by this study will be critical for assessing potential of the candidate to advance into late-stage clinical trials and towards our goal, at CEPI, to get a licensed Lassa vaccine for use in endemic countries."
Professor Dorothy Yeboah-Manu, Director of the Noguchi Memorial Institute for Medical Research (NMIMR) in Ghana, said, "This achievement is another feather in our cap that goes to demonstrate the expertise and dedication of the NMIMR in the global fight against infectious diseases. As a leading biomedical institute in the West African sub region and considering the public health importance of Lassa fever in West Africa, we are happy to be part of INO-4500 development, indeed the fight against these emerging infections requires us to work together and we look forward to such further collaborations."
Professor Kwadwo Koran, the PI for the Noguchi Memorial Institute for Medical Research site in Ghana, said, "It has been exciting working on this trial, a great achievement for the Institute and the country as whole. Personally, I see this as NMIMR continuing in the noble ideals of contributing to solutions for public health problems in the sub region. With the successful enrollment, even under the trying conditions engendered by the COVID-19 pandemic for nearly two years now, the Institute and indeed the country as a whole has demonstrated the capacity to be able to conduct early-stage trials in support of product development for emerging and re-emerging diseases such as Lassa Fever. It is my sincere hope that this will be built upon not only for Lassa Fever but other important infections that plague us."
About INOVIO's Phase 1B Clinical Trial for INO-4500
INOVIO's Phase 1B clinical trial, LSV-002, a randomized, blinded, placebo-controlled dose ranging study enrolled 220 healthy adult participants between the ages of 18-50 years old, with the primary endpoints of evaluating safety and immunogenicity profile of INO-4500 DNA vaccine candidate, administered by intradermal (ID) injection followed by electroporation (EP) using CELLECTRA(TM) 2000 device in Ghana. The dosing regimen involved two intradermal vaccinations at 0 and 28 days with either 1.0 mg or 2.0 mg doses. In addition to providing insights on the INO-4500 safety and immunogenicity profile, this trial will inform dose selection for subsequent Phase 2 studies in West Africa.
Since its establishment in 1979, the Noguchi Memorial Institute for Medical Research (NMIMR) has gained global recognition as a leading biomedical research institute in Africa, building capacity for prevention and control of endemic diseases, as well as emerging and re-emerging diseases, in Ghana and the West African sub-region. The Institute has been a leader in developing effective diagnosis capabilities and clinical research for the treatment and protection against HIV/AIDS, H1N1 Pandemic Flu, Lassa fever, Yellow fever, Ebola Virus Disease and malaria. The clinical Principal Investigator for LSV-002 is Professor Dr. Kwadwo A. Koram, an expert and specialist in tropical medicines and epidemiologist with more than 20 years of research experience, including malaria vaccines.
About Lassa Fever
Lassa fever is an animal-borne, acute hemorrhagic viral illness primarily observed in parts of West Africa. Infection is spread through contact with infected rodents, as well as person-to-person transmission via bodily fluids (primarily in health care settings). The disease can cause a range of outcomes, including fever, vomiting, and swelling of the face, pain in the chest, back and abdomen, bleeding of various parts of the body including the eyes and nose and death. Of the survivors of Lassa fever, about one-third have sudden-onset hearing loss, with more than half of those cases resulting in permanent hearing loss [Mateer et al. PLoS Negl Trop Dis (2018)].
In addition to funding INOVIO's Lassa vaccine candidate, CEPI has therefore also created and funded the largest ever Lassa fever study, named Enable, to provide a more accurate assessment of the incidence of Lassa fever infections in West Africa. The Enable study aims to better understand the rate, location, and spread of Lassa virus across the region.
Data from CEPI's Enable study will also guide the location and implementation of future late-stage Lassa vaccine efficacy trials.
Lassa virus infection in West Africa is estimated to affect 100,000 to 300,000 people annually, and it is responsible for 10 -- 16% of hospital admissions in some parts of Liberia and Sierra Leone [US CDC (2019)]. The virus is responsible for approximately 5,000 deaths annually [US CDC (2019)]. Over the last five decades, outbreaks in Nigeria for example have worsened, with increased frequency and geographic breadth, and during this time a broader spread has occurred within West Africa and possibly into West-Central Africa [Agbonlahor et al. Am J Trop Med Hyg (2021)]. The World Health Organization (WHO) classifies Lassa virus as one of the pathogens with epidemic potential to be urgently addressed, thereby making the development of safe and effective vaccines a global health priority [WHO (2016)].
Because of difficulties in diagnosing Lassa fever, the lack of standardized surveillance assays, and the remote nature of many of the areas in West Africa where outbreaks typically occur, the numbers of reported cases and deaths may be lower than the actual numbers of cases and deaths. Though the majority (about 80%) of Lassa virus-infected persons are asymptomatic or have mild symptoms, the infection can be quite serious or fatal in others [WHO (undated)]. The case-fatality ratio (CFR), aka case-fatality rate, among patients hospitalized for Lassa fever is about 15 -- 20%, and, in some epidemics the case-fatality rate has reached 50% in hospitalized patients [Brosh-Nissimov Disaster Mil Med (2016)]. The CFR among pregnant women is particularly high, and in pregnant women infected with Lassa virus the fetal death rate due to spontaneous abortion rate is estimated to be extremely high at about 95% [WHO (2017); US CDC (2014)].
Agbonlahor DE, Akpede GO, Happi CT, Tomori O. 52 Years of Lassa Fever Outbreaks in Nigeria, 1969-2020: An Epidemiologic Analysis of the Temporal and Spatial Trends. Am J Trop Med Hyg. 2021 Aug 30:tpmd201160. doi: 10.4269/ajtmh.20-1160. Epub ahead of print. PMID: 34460421.
Brosh-Nissimov T. Lassa fever: another threat from West Africa. Disaster Mil Med. 2016 Apr 30;2:8. doi: 10.1186/s40696-016-0018-3. PMID: 28265442; PMCID: PMC5330145
Centers for Disease Control and Prevention, United States of America. Lassa Fever. 2019. https://www.cdc.gov/vhf/lassa/index.html [accessed Oct. 13, 2021]
Centers for Disease Control and Prevention, United States of America. Lassa Fever Fact sheet. 2014. https://www.cdc.gov/vhf/lassa/pdf/factsheet.pdf [accessed Oct. 13, 2021].
Mateer EJ, Huang C, Shehu NY, Paessler S. Lassa fever-induced sensorineural hearing loss: A neglected public health and social burden. PLoS Negl Trop Dis. 2018 Feb 22;12(2):e0006187.
2021-10-26 12:00:00 GMT INOVIO Completes Enrollment of Phase 1B Clinical -2-
World Health Organization. An R&D Blueprint for Action to Prevent Epidemics. Plan of Action. May 2016.
World Health Organization. Health Topics -- Lassa Fever. (undated). https://www.who.int/health-topics/lassa-fever#tab=tab\_1 [Accessed Jan. 7, 2021].
World Health Organization. Lassa Fever. 2017. https://www.who.int/news-room/fact-sheets/detail/lassa-fever [accessed Oct. 13, 2021].
submitted by Huck_el_berry to Inovio [link] [comments]
2021.10.26 09:10 Gummy-Something Make some assumptions about me, literally anything you want.
|submitted by Gummy-Something to teenagers [link] [comments]|
2021.10.26 09:10 agentbrown12 Apex shield is bugged